Microsoft Technology Center to Host BioClinica User Meeting

Enterprise-Wide Cost Efficiencies and Trial Standardization Results Ahead of Targets

NEWTOWN, Pa.--(BUSINESS WIRE)-- BioClinica®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, announced that Microsoft will host the upcoming 2011 BioClinica User Conference. This meeting will offer participants insightful user presentations and case studies, interactive breakout group sessions, and updates on BioClinica’s product roadmap and corporate vision. Activities also include the opportunity to network with colleagues with similar interests and experiences.

“We appreciate the opportunity for Microsoft to host this important event for BioClinica’s clients,” said Steve Aylward, General Manager, Microsoft US Commercial Health & Life Sciences. “Microsoft and BioClinica are working together to deliver superior technology solutions that support clinical research. Bringing users and partners together at this event will improve understanding of BioClinica’s vision for their products while encouraging collaboration and sharing best practices that will lead to more efficient clinical trials.”

This year’s meeting will be held in Malvern, PA and will be comprised of users of BioClinica’s complete suite of eClinical applications, including: Express EDC, Trident IWR, OnPoint CTMS and Optimizer supplies forecasting.

When: October 25 – October 26, 2011

Where: Microsoft Technology Center, 45 Liberty Boulevard, Malvern, PA 19355

“There has never been a better time to be a BioClinica partner,” said Peter Benton, President of eClinical Solutions for BioClinica. “BioClinica’s combination of transformative technology and service innovation provides clients with a huge opportunity to successfully address many of the challenges they face in the execution of global clinical studies. We are grateful to Microsoft for their ongoing alliance and support as well as for hosting our 2011 BioClinica User Conference.”

Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.



CONTACT:

BioClinica, Inc.
Jim Dorsey, 267-757-3040
or
Diccicco Battista Communications
Trade Media – Rachel Summers
484-342-3600
or
Porter, LeVay & Rose, Inc.
Investor Contact - Michael Porter
Financial Media - Bill Gordon
212-564-4700

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:   Technology  Data Management  Software  Health  Biotechnology  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.